Mesoblast Participation at Piper Sandler Conference

Mesoblast is pleased to be partnering with @UnitedHealthGrp's @Optum Frontier Therapeutics to rapidly deliver our cellular therapy to children with life-threatening acute steroid-refractory Graft Versus Host Disease. Learn more here: https://t.co/xUCZQ8T9eV

James M. O’Brien Appointed Chief Financial Officer at Mesoblast

Mesoblast to Meet With FDA Next Month to Discuss Rexlemestrocel-L and Opioid Cessation

Ryoncil® Net Revenues Increase 69% in Second Quarter Post Launch

Ryoncil® Revenues Increase 66% in Second Quarter Post Launch

Ryoncil® Receives J-Code From Medicare & Medicaid Services (CMS) Facilitating Reimbursement and Broader Patient Access

Successful Commercial Launch of Ryoncil® Highlighted at Global Healthcare Conferences

Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board

We are pleased to announce that Ryoncil® (remestemcel-L) for pediatric patients with SR-aGvHD is commercially available in the United States. Learn more at our patient resource center and get access to specialists and support programs: https://t.co/Zb9NGQAHuX #Ryoncil

Mesoblast CEO to Deliver Featured Presentation at ISCT North America Virtual Town Hall

Mesoblast Added to S&P/ASX 200 INDEX

Mesoblast Sets Ryoncil® Price Based on Economic Value of Treatment With Planned Product Availability This Quarter

Mesoblast Financial Results and Corporate Update Webcast

Dr. Gregory George MD PhD Joins Mesoblast Board

We had a great time meeting everyone at the @ASTCT meetings last week! Missed us at the show? Learn more about our latest FDA-approved cell therapy here: https://t.co/IOLHZZkwcO

Are you at the @ASTCT Transplantation and Cellular Therapy Meetings in Honolulu this week? Come see us at booth 137 to learn more about Ryoncil (remestemcel-L) for pediatric patients with SR-aGvHD! Please see full prescribing information for more details. https://t.co/Zb9NGQAHuX

Join us at @ASTCT in Honolulu! On Feb 14, we’re hosting a reception at the Hilton Hawaiian Village where attendees can meet investigators from the Phase 3 trial on SR-aGvHD in children. Don’t miss this chance to learn about our new treatment! https://t.co/L99UYIqKba #ASTCT.

Mesoblast updates on the progress of the U.S. commercial launch of Ryoncil® and key upcoming milestones for its late-stage pipeline

Mesoblast’s RYONCIL® is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy